



MARKET RELEASE

17 April 2014

QRxPharma Limited

TRADING HALT

The securities of QRxPharma Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 24 April 2014 or when the announcement is released to the market.

Security Code: QRX

Stephanie Yong
Senior Adviser, Listings Compliance (Sydney)



17 April 2014

ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Attention: Stephanie Yong

Dear Stephanie,

Request for Trading Halt – QRxPharma Limited (QRxPharma)

In accordance with Listing Rule 17.1, QRxPharma requests an immediate trading halt in its ordinary securities listed on the ASX.

The Advisory Committee meeting set by the United States Food and Drug Administration (**FDA**) in relation to QRxPharma's resubmitted Moxduo[®] New Drug Application (**NDA**) is being held on Tuesday, 22 April 2014 (U.S. time). It is expected that the briefing information for the Advisory Committee meeting will be released on the FDA website on Friday, 18 April 2014 (U.S. time) in accordance with the FDA's standard process and the proceedings of the Advisory Committee will be webcast live. QRxPharma will not be in a position to comment on the briefing materials or the outcome of the Advisory Committee meeting until the meeting has concluded and the results are known and have been considered by QRxPharma.

QRxPharma expects to be able to make an announcement in relation to the outcome of the Advisory Committee meeting on the morning of Wednesday, 23 April 2014.

QRxPharma also advises the following, as required under Listing Rule 17.1:

1. QRxPharma requests the trading halt to last until an announcement in relation to the results of the Advisory Committee meeting is released – expected to be the morning of Wednesday, 23 April 2014; and
2. QRxPharma is not aware of any reason why the trading halt should not be granted by the ASX and is not aware of any other information that is necessary to inform the market about the trading halt.

Please contact me if you have any queries.

Yours sincerely

A handwritten signature in blue ink that reads 'C. J. Campbell'.

Chris J Campbell
Company Secretary

QRxPharma Limited